PURPOSE 2: Endorsement and Anticipated Challenges to Adopting Twice-Yearly Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) Among Cisgender Men Who Have Sex With Men (MSM): Qualitative Insights from the PURPOSE 2 Trial

Conference Reports for NATAP

13th IAS Conference on HIV Science
IAS 2026
July 26-31 Rio, Brazil


PURPOSE 2: Endorsement and Anticipated Challenges to Adopting Twice-Yearly Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) Among Cisgender Men Who Have Sex With Men (MSM): Qualitative Insights from the PURPOSE 2 Trial

	IAS 2026 Rio, Brazil